Who's who · AI in biology and medicine
Recursion
Recursion uses automated labs and AI models to discover drugs, both on its own and with partners such as Sanofi and Roche/Genentech.
Why it matters: It is the largest listed 'AI-first' drug discovery company, and its clinical results are a public scorecard for the approach.
Key facts
- Its lead drug REC-4881 cut median polyp burden 43% after three months in a Phase 2 trial in FAP patients.Source: recursion.com, as of Aug 2026
- Had about $557 million in cash in August 2026, which it said funds operations into early 2028; it cut 2026 cash operating expenses guidance to $375 million.Source: recursion.com, as of Aug 2026
- Its Roche/Genentech collaboration has brought in more than $216 million in upfront and milestone payments.Source: recursion.com, as of Aug 2026
Our latest stories
No stories about Recursion in our recent coverage yet. New ones appear here as they publish.